WO2004108726A1 - Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie - Google Patents
Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie Download PDFInfo
- Publication number
- WO2004108726A1 WO2004108726A1 PCT/CN2004/000487 CN2004000487W WO2004108726A1 WO 2004108726 A1 WO2004108726 A1 WO 2004108726A1 CN 2004000487 W CN2004000487 W CN 2004000487W WO 2004108726 A1 WO2004108726 A1 WO 2004108726A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- phenyl
- straight
- branched alkyl
- propyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT04732925T ATE491710T1 (de) | 2003-06-06 | 2004-05-14 | 2-substituierte phenyl-5,7-dialkyl-3,7- dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung |
BRPI0411402-7A BRPI0411402A (pt) | 2003-06-06 | 2004-05-14 | derivados de fenil-5, 7-di-hidrocarbil-3, 7di-hidropirrolo [2,3-d] pirimidin-4-ona 2-substituìda, sua preparação e seu uso farmacêutico |
CA2528008A CA2528008C (en) | 2003-06-06 | 2004-05-14 | 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
AP2006003481A AP2329A (en) | 2003-06-06 | 2004-05-14 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2,3-d] pyrimidin-4 - one derivatives, the preparation and the pharmaceutical use thereof. |
MXPA05013176A MXPA05013176A (es) | 2003-06-06 | 2004-05-14 | 2-sustituido fenil-5, 7-dihidrocarbil-3, 7-dihidropirrolo [2,3-d] pirimidin-4-un derivativos, su preparacion y uso farmaceutico. |
JP2006508096A JP4917428B2 (ja) | 2003-06-06 | 2004-05-14 | 2−置換フェニル−5,7−ジアルキル−3,7−ジヒドロピロロ[2,3−d]ピリミジン−4−オン誘導体、その製法およびその医薬用途 |
US10/559,516 US7745433B2 (en) | 2003-06-06 | 2004-05-14 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
DE602004030564T DE602004030564D1 (de) | 2003-06-06 | 2004-05-14 | 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung |
EP04732925A EP1634883B1 (en) | 2003-06-06 | 2004-05-14 | 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole[2,3-d] pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof |
IL172369A IL172369A (en) | 2003-06-06 | 2005-12-05 | History of 2-Transformed Phenyl-5, 7-Dialkyl-3, 7-Dihydropyrrolo- [3,2-d] Pyrimidin-4-Ven, process for their preparation, and pharmaceutical preparations containing them |
KR1020057023465A KR101081446B1 (ko) | 2003-06-06 | 2005-12-06 | 2-치환페닐-5,7-디알킬-3,7-디하이드로피롤[2,3-d]피리미딘-4-온유도체, 그의 제법 및 약학적 용도 |
US12/043,700 US7741483B2 (en) | 2003-06-06 | 2008-03-06 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 |
US12/685,376 US8461165B2 (en) | 2003-06-06 | 2010-01-11 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB03142399XA CN100374441C (zh) | 2003-06-06 | 2003-06-06 | 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途 |
CN03142399.X | 2003-06-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/559,516 A-371-Of-International US7745433B2 (en) | 2003-06-06 | 2004-05-14 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
US12/043,700 Division US7741483B2 (en) | 2003-06-06 | 2008-03-06 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004108726A1 true WO2004108726A1 (fr) | 2004-12-16 |
Family
ID=33494609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000487 WO2004108726A1 (fr) | 2003-06-06 | 2004-05-14 | Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie |
Country Status (15)
Country | Link |
---|---|
US (3) | US7745433B2 (zh) |
EP (1) | EP1634883B1 (zh) |
JP (1) | JP4917428B2 (zh) |
KR (1) | KR101081446B1 (zh) |
CN (1) | CN100374441C (zh) |
AP (1) | AP2329A (zh) |
AT (1) | ATE491710T1 (zh) |
BR (1) | BRPI0411402A (zh) |
CA (1) | CA2528008C (zh) |
DE (1) | DE602004030564D1 (zh) |
IL (1) | IL172369A (zh) |
MX (1) | MXPA05013176A (zh) |
RU (1) | RU2323220C2 (zh) |
WO (1) | WO2004108726A1 (zh) |
ZA (1) | ZA200600107B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066111A1 (zh) | 2008-12-10 | 2010-06-17 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100792126B1 (ko) | 2006-04-04 | 2008-01-04 | 동아제약주식회사 | 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제 |
CN101456862B (zh) * | 2007-12-12 | 2012-10-24 | 上海特化医药科技有限公司 | 含有吡唑并嘧啶酮的苯基胍衍生物、其药物组合物及其制备方法和用途 |
AR077898A1 (es) | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
CN102311447B (zh) * | 2010-07-07 | 2013-11-27 | 中国科学院广州生物医药与健康研究院 | 杂环并嘧啶酮类dpp-iv抑制剂 |
CN102311448B (zh) * | 2010-07-07 | 2014-02-19 | 中国科学院广州生物医药与健康研究院 | 噻吩并嘧啶酮类dpp-iv抑制剂 |
US20140072557A1 (en) * | 2011-02-28 | 2014-03-13 | National Cerebral And Cardiovascular Center | Medicinal agent for suppressing malignant tumor metastasis |
RU2014151004A (ru) * | 2012-06-07 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы |
CN104530054B (zh) * | 2014-12-19 | 2018-01-19 | 扬子江药业集团有限公司 | 盐酸优克那非的多晶型物及其制备方法 |
CN114042071A (zh) * | 2015-07-08 | 2022-02-15 | 珠海津之敦医药科技有限公司 | 尤克那非新用途 |
US11155558B2 (en) * | 2017-05-22 | 2021-10-26 | Topadur Pharma Ag | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
CN112266349B (zh) * | 2020-11-17 | 2022-02-15 | 上海凌凯医药科技有限公司 | 一种制备2-氨基-4-甲基-1-丙基-1h-吡咯-3-甲腈的方法 |
CN112961160A (zh) * | 2021-03-05 | 2021-06-15 | 遂成药业股份有限公司 | 一种西地那非的改良合成工艺 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028902A1 (en) | 1993-06-09 | 1994-12-22 | Pfizer Limited | Pyrazolopyrimidinones for the treatment of impotence |
WO1998049116A1 (en) | 1997-04-30 | 1998-11-05 | Crosfield Limited | Suspensions with high storage stability, comprising an aqueous silicate solution and a filler material |
WO2000024745A1 (en) | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
WO2000027848A1 (en) | 1998-11-11 | 2000-05-18 | Dong A Pharm. Co., Ltd. | Pyrazolopyrimidinone derivatives for the treatment of impotence |
US6100270A (en) | 1994-11-26 | 2000-08-08 | Pfizer Inc. | Bicyclic heterocyclic compounds for the treatment of impotence |
US6251904B1 (en) | 1998-04-20 | 2001-06-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
WO2001060825A1 (en) | 2000-02-17 | 2001-08-23 | Sk Chemicals Co., Ltd. | Pyrrolopyrimidinone derivatives, process of preparation and use |
WO2001098304A1 (en) | 2000-06-23 | 2001-12-27 | Dong A Pharm. Co., Ltd. | A process for preparing pyrazolopyrimidinone derivatives for the treatment of impotence |
DE19881732C1 (de) | 1997-11-12 | 2002-01-31 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone |
WO2002016364A1 (en) | 2000-08-23 | 2002-02-28 | Lg Life Sciences Ltd. | Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5235053A (en) * | 1992-06-22 | 1993-08-10 | Eli Lilly And Company | Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
JP4166859B2 (ja) * | 1997-03-17 | 2008-10-15 | 富士フイルム株式会社 | 2−アミノピロール誘導体及びその製造方法 |
DE29806778U1 (de) | 1998-04-15 | 1999-09-02 | Grote & Hartmann | Schraubanschluß |
US6878716B1 (en) * | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
IN186584B (zh) | 1999-03-26 | 2001-10-06 | Kopran Ltd | |
GB9909135D0 (en) * | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
GB9924020D0 (en) | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Pharmaceutically active compounds |
US6849735B1 (en) * | 2000-06-23 | 2005-02-01 | Merck Eprova Ag | Methods of synthesis for 9-substituted hypoxanthine derivatives |
GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
-
2003
- 2003-06-06 CN CNB03142399XA patent/CN100374441C/zh not_active Expired - Lifetime
-
2004
- 2004-05-14 EP EP04732925A patent/EP1634883B1/en active Active
- 2004-05-14 DE DE602004030564T patent/DE602004030564D1/de active Active
- 2004-05-14 BR BRPI0411402-7A patent/BRPI0411402A/pt not_active Application Discontinuation
- 2004-05-14 WO PCT/CN2004/000487 patent/WO2004108726A1/zh active Application Filing
- 2004-05-14 AP AP2006003481A patent/AP2329A/xx active
- 2004-05-14 MX MXPA05013176A patent/MXPA05013176A/es active IP Right Grant
- 2004-05-14 RU RU2005141447/04A patent/RU2323220C2/ru active
- 2004-05-14 US US10/559,516 patent/US7745433B2/en active Active
- 2004-05-14 JP JP2006508096A patent/JP4917428B2/ja active Active
- 2004-05-14 AT AT04732925T patent/ATE491710T1/de not_active IP Right Cessation
- 2004-05-14 CA CA2528008A patent/CA2528008C/en active Active
-
2005
- 2005-12-05 IL IL172369A patent/IL172369A/en not_active IP Right Cessation
- 2005-12-06 KR KR1020057023465A patent/KR101081446B1/ko active IP Right Grant
-
2006
- 2006-01-05 ZA ZA200600107A patent/ZA200600107B/en unknown
-
2008
- 2008-03-06 US US12/043,700 patent/US7741483B2/en active Active
-
2010
- 2010-01-11 US US12/685,376 patent/US8461165B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028902A1 (en) | 1993-06-09 | 1994-12-22 | Pfizer Limited | Pyrazolopyrimidinones for the treatment of impotence |
US6100270A (en) | 1994-11-26 | 2000-08-08 | Pfizer Inc. | Bicyclic heterocyclic compounds for the treatment of impotence |
WO1998049116A1 (en) | 1997-04-30 | 1998-11-05 | Crosfield Limited | Suspensions with high storage stability, comprising an aqueous silicate solution and a filler material |
DE19881732C1 (de) | 1997-11-12 | 2002-01-31 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone |
US6251904B1 (en) | 1998-04-20 | 2001-06-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
WO2000024745A1 (en) | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
WO2000027848A1 (en) | 1998-11-11 | 2000-05-18 | Dong A Pharm. Co., Ltd. | Pyrazolopyrimidinone derivatives for the treatment of impotence |
WO2001060825A1 (en) | 2000-02-17 | 2001-08-23 | Sk Chemicals Co., Ltd. | Pyrrolopyrimidinone derivatives, process of preparation and use |
CN1422271A (zh) * | 2000-02-17 | 2003-06-04 | Sk化学株式会社 | 吡咯并嘧啶酮衍生物,其制备方法及用途 |
WO2001098304A1 (en) | 2000-06-23 | 2001-12-27 | Dong A Pharm. Co., Ltd. | A process for preparing pyrazolopyrimidinone derivatives for the treatment of impotence |
WO2002016364A1 (en) | 2000-08-23 | 2002-02-28 | Lg Life Sciences Ltd. | Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence |
Non-Patent Citations (4)
Title |
---|
EGER K. ET AL.: "Synthesis of pyrrolo[2,3-d]pyrimidine ribosides and their potential in chemotherapeutics", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 27, no. 7, 1990, pages 2069 - 2075, XP000655185 * |
MATTSON J. ET AL.: "Selective N-1-methylation of 2-aminopyrroles with sodium hydride and dimethyl sulfate", SYNTHESIS, no. 3, 1979, pages 217 - 218, XP002016121 * |
PICHLER H. ET AL.: "Synthesis of 7-unsubstituted 7H-pyrrolo[2,3-d]pyrimidines", LIEBIGS ANNALEN DER CHEMIE, no. 9, 1986, pages 1485 - 1505, XP002059629 * |
SHEN J. ET AL.: "Synthesis of sildenafil", ZHONGGUO YAOWU HUAXUE ZAZHI, vol. 9, no. 3, 1999, pages 220 - 222, XP008095114 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066111A1 (zh) | 2008-12-10 | 2010-06-17 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
US8871777B2 (en) | 2008-12-10 | 2014-10-28 | Topharman Shanghai Co., Ltd. | Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1552714A (zh) | 2004-12-08 |
JP4917428B2 (ja) | 2012-04-18 |
US20100204223A1 (en) | 2010-08-12 |
US20060173025A1 (en) | 2006-08-03 |
US7741483B2 (en) | 2010-06-22 |
ATE491710T1 (de) | 2011-01-15 |
IL172369A0 (en) | 2006-04-10 |
AP2329A (en) | 2011-12-02 |
CN100374441C (zh) | 2008-03-12 |
US8461165B2 (en) | 2013-06-11 |
AP2006003481A0 (en) | 2006-02-28 |
JP2008500944A (ja) | 2008-01-17 |
CA2528008C (en) | 2010-02-16 |
IL172369A (en) | 2014-01-30 |
US20080167462A1 (en) | 2008-07-10 |
EP1634883B1 (en) | 2010-12-15 |
KR101081446B1 (ko) | 2011-11-08 |
CA2528008A1 (en) | 2004-12-16 |
RU2323220C2 (ru) | 2008-04-27 |
DE602004030564D1 (de) | 2011-01-27 |
KR20060036396A (ko) | 2006-04-28 |
RU2005141447A (ru) | 2007-07-20 |
EP1634883A1 (en) | 2006-03-15 |
US7745433B2 (en) | 2010-06-29 |
EP1634883A4 (en) | 2008-07-02 |
ZA200600107B (en) | 2007-04-25 |
BRPI0411402A (pt) | 2006-10-31 |
MXPA05013176A (es) | 2006-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8461165B2 (en) | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | |
US6677335B1 (en) | Pharmaceutically active compounds | |
TWI265031B (en) | Novel pharmaceuticals | |
US20060041124A1 (en) | Process for preparing pyrrolotriazine kinase inhibitors | |
JP2001151778A (ja) | 薬学的に活性な化合物 | |
ES2345207T3 (es) | Compuestos pirazolo-heteroarilicos utiles para tratar enfermedades mediadas por tnf-alfa e il-1. | |
JP2004527510A (ja) | CGMPPDE阻害剤としてのピラゾロ[4,3−d]ピリミジノン化合物 | |
JP2004517828A (ja) | 新規なスルホンアミド置換ピラゾロピリジン誘導体 | |
JP4363530B2 (ja) | タンパク質キナーゼ阻害剤 | |
EP2253632A1 (en) | Pyrazolopyramidinone derivatives, their preparation and their use | |
JP2019519534A (ja) | 五員複素環[3,4−d]ピリダジノン系化合物、その製造方法、医薬組成物及び応用 | |
DE602004012146T2 (de) | Pyrazolopyrimidine | |
WO2004101567A1 (fr) | Derives de 2-phenyl substitue -6,8-dialkyl-3h-imidazole [1,5a] [1,3,5] triazine-4- one, preparation et utilisation pharmaceutique associees | |
KR100297814B1 (ko) | 피라졸로피리미디논유도체와이의제조방법그리고이의용도 | |
SK572003A3 (en) | Crystalline therapeutic agent | |
CA1071207A (en) | 4-amino derivatives of 2h-pyrazolo (3,4-b) pyridine-5-carboxylic acids and esters | |
JP2004505980A (ja) | ピロロトリアゾロピリミジノン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2528008 Country of ref document: CA Ref document number: 2006508096 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 172369 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/013176 Country of ref document: MX Ref document number: 1020057023465 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12005502231 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004732925 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501925 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/00107 Country of ref document: ZA Ref document number: 200600107 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005141447 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004732925 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006173025 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10559516 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057023465 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10559516 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0411402 Country of ref document: BR |